These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8636429)

  • 1. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van 't Hof HB; Mol MJ; van der Boom H; van der Zee A; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1996 Mar; 97(5):1184-92. PubMed ID: 8636429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van den Maagdenberg AM; Gijbels MJ; van der Boom H; HogenEsch H; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1994 Apr; 93(4):1403-10. PubMed ID: 8163645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.
    Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM
    J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B.
    Shimano H; Yamada N; Katsuki M; Yamamoto K; Gotoda T; Harada K; Shimada M; Yazaki Y
    J Clin Invest; 1992 Nov; 90(5):2084-91. PubMed ID: 1430232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
    de Knijff P; van den Maagdenberg AM; Stalenhoef AF; Leuven JA; Demacker PN; Kuyt LP; Frants RR; Havekes LM
    J Clin Invest; 1991 Aug; 88(2):643-55. PubMed ID: 1864973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; van Dijk KW; van't Hof HB; van Gorp PJ; van der Zee A; van der Boom H; Breuer ML; Hofker MH; Havekes LM
    J Biol Chem; 1996 Nov; 271(48):30595-602. PubMed ID: 8940032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice.
    van Vlijmen BJ; Mensink RP; van 't Hof HB; Offermans RF; Hofker MH; Havekes LM
    J Lipid Res; 1998 Jun; 39(6):1181-8. PubMed ID: 9643349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes.
    Kuipers F; Jong MC; Lin Y; Eck M; Havinga R; Bloks V; Verkade HJ; Hofker MH; Moshage H; Berkel TJ; Vonk RJ; Havekes LM
    J Clin Invest; 1997 Dec; 100(11):2915-22. PubMed ID: 9389759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dietary cholesterol on hepatic production of lipids and lipoproteins in isolated hamster liver.
    Chen J; Song W; Redinger RN
    Hepatology; 1996 Aug; 24(2):424-34. PubMed ID: 8690415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.
    Venkatesan N; Devaraj SN; Devaraj H
    Eur J Nutr; 2003 Oct; 42(5):262-71. PubMed ID: 14569407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice.
    Mensenkamp AR; van Luyn MJ; van Goor H; Bloks V; Apostel F; Greeve J; Hofker MH; Jong MC; van Vlijmen BJ; Havekes LM; Kuipers F
    J Hepatol; 2000 Aug; 33(2):189-98. PubMed ID: 10952236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.
    Demant T; Bedford D; Packard CJ; Shepherd J
    J Clin Invest; 1991 Nov; 88(5):1490-501. PubMed ID: 1939641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis.
    Post SM; de Roos B; Vermeulen M; Afman L; Jong MC; Dahlmans VE; Havekes LM; Stellaard F; Katan MB; Princen HM
    Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1551-6. PubMed ID: 10845871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype.
    Dergunov AD; Novoselov AV; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biol Chem; 2005 May; 386(5):441-52. PubMed ID: 15927888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.
    Jong MC; van Dijk KW; Dahlmans VE; Van der Boom H; Kobayashi K; Oka K; Siest G; Chan L; Hofker MH; Havekes LM
    Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):281-7. PubMed ID: 10024503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
    Kypreos KE; Li X; van Dijk KW; Havekes LM; Zannis VI
    Biochemistry; 2003 Aug; 42(33):9841-53. PubMed ID: 12924933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia.
    van den Maagdenberg AM; Hofker MH; Krimpenfort PJ; de Bruijn I; van Vlijmen B; van der Boom H; Havekes LM; Frants RR
    J Biol Chem; 1993 May; 268(14):10540-5. PubMed ID: 7683682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.